Time to Take Action logo

Intervene before OHE strikes again

An overt hepatic encephalopathy (OHE) recurrence can happen at any moment.1 That’s why it’s critical to take the time to evaluate patients, consider their risk for recurrence, and determine a course of action.

While each patient with OHE has their own medical history and array of OHE experiences, they all depend on you to guide their care.

Take on this interactive challenge and determine what you would do for each of these patients.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.